Insulin-AKT1-YBX1 Regulation of ANGPTL8 Promote Lipogenesis in OSA-Associated Dyslipidemia

Feng Liu,Yuenan Liu,Haolin Yuan,Anzhao Wang,Shengming Wang,Xu Xu,Junhui Hu,Jinhong Shen,Yiming Hu,Xinyi Li,Niannian Li,Zhenfei Gao,Xiaoxu Zhang,Xiaoman Zhang,Yupu Liu,Huajun Xu,Hongliang Yi,Jian Guan,Zhiqiang Li,Yongxu Zhao,Shankai Yin

DOI: https://doi.org/10.1101/2024.06.23.24309370

2024-06-24

Abstract:Dyslipidemia is a hallmark of obstructive sleep apnea (OSA)-induced metabolic syndrome, yet the mechanisms remain poorly understood. We conducted a genome-wide association study on lipid traits in the OSA cohorts, identifying the SNP rs3745683 in ANGPTL8, significantly associated with reductions in multiple lipid traits. ANGPTL8, an essential lipogenic hormone and potential therapeutic target for metabolic syndrome, showed elevated expression in OSA patients compared to healthy controls, strongly correlated with increased insulin levels. Notably, ANGPTL8 expression can be upregulated by insulin stimulation, indicating it as an insulin-responsive hormone regulating dyslipidemia in OSA. Mechanistically, SNP rs3745683 attenuated ANGPTL8 transcription by inhibiting its binding to transcription factor YBX1. Insulin prompted AKT1 to phosphorylate YBX1 at Ser102, facilitating YBX1's nuclear translocation and subsequent regulation of ANGPTL8 expression and lipid synthesis. Specific knockdown of YBX1 in mouse liver confirmed its necessity for ANGPTL8 expression and hepatic lipid synthesis in vivo. Our findings highlight ANGPTL8 as a critical regulator of dyslipidemia in OSA patients, offering a promising therapeutic avenue for managing metabolic syndrome in OSA.

Respiratory Medicine